Published: 18-11-2026 14:15 | Updated: 18-11-2026 14:18

Engineered protein targets antibiotic-resistant bacteria and toxins in bacterial meningitis

Microscope close up of meningitis bacteria, also known as meningococcus 3D Illustration
Image: EnzumeImages/Gettyimages

Researchers at Karolinska Institutet have developed an engineered antibacterial protein that can kill antibiotic-resistant bacteria while also neutralising toxins released by the bacteria. In a new study published in Molecular Medicine, the approach reduced harmful inflammation and neuronal damage in experimental models of bacterial meningitis.

Bacterial meningitis is a medical emergency that can lead to death or lifelong neurological complications. Treatment can be particularly challenging when the infection is caused by antibiotic-resistant bacteria. Antibiotics may also have difficulty crossing the blood-brain barrier, which protects the brain from substances circulating in the blood but is also a barrier for drugs and therapeutics. 

The researchers therefore investigated a different approach based on an endolysin, a protein enzyme derived from bacteriophages, viruses that infect bacteria. They engineered the natural endolysin Cpl-1 by attaching a peptide that binds to pneumolysin, a major toxin released by Streptococcus pneumoniae, also known as pneumococcus, the major cause of bacterial meningitis globally. 

Two targets at the same time

The resulting chimeric protein was designed to perform two tasks: kill the bacteria, especially the ones resistant to antibiotic treatment, and neutralise the toxin that can contribute to inflammation and damage to nerve cells. It was tested using biochemical and microbiological methods, cell-based experiments and a mouse model of meningitis. 

Portrait, close-up.
Federico Iovino. Photo: N/A

“With this approach, we wanted to address two important causes of damage at the same time: the bacterial infection itself and the harmful effects of the toxins released by the bacteria,” says corresponding author Federico Iovino, associate professor at the Department of Neuroscience.

In mice with meningitis caused by penicillin-resistant pneumococci, the engineered endolysin eliminated the bacteria both in the blood and in the brain. The treatment also reduced the harmful inflammation and neuronal injury associated with toxin release.

More research needed

The results provide proof of concept for the approach, but it is not yet a treatment for patients. The researchers now plan to investigate delivery, dosage and pharmacological properties and to test the method in models that more closely resemble the clinical situation.

They are also exploring whether the same principle could be used against other antibiotic-resistant bacteria that cause bloodstream infections, sepsis and central nervous system infectious diseases. 

“The next step is to optimise the treatment and test it in increasingly translational models of meningitis before it can move towards clinical development,” says Federico Iovino.

The study was supported by the Swedish Research Council, Torsten Söderberg Foundation, Novo Nordisk Foundation, Karolinska Institutet, StratNeuro and H.K.H. Crown Princess Lovisa's Association for Child Care. The biochemical characterisation was carried out in collaboration with the laboratory of Daniel C Nelson at the Institute for Bioscience and Biotechnology Research, University of Maryland, USA.

Publication

Engineered cpl-1 endolysin for dual-action treatment of central nervous system bacterial infections: killing antibiotic-resistant bacteria and neutralizing released toxins
Niels Vander Elst, Lotte Merlijn, Kristine Farmen, Valentina Mocci, Clara Caceffo, Daniel Kemboi, Adit B. Alreja, Daniel C. Nelson & Federico Iovino
Molecular Medicine, 14 November 2026, doi: 10.1186/s10020-026-01697-w